06.12.2012 Views

Guidelines for malaria prevention in travellers from the United ...

Guidelines for malaria prevention in travellers from the United ...

Guidelines for malaria prevention in travellers from the United ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

G UIDELINES FOR M ALARIA P REVENTION IN<br />

T RAVELLERS FROM THE U NITED K INGDOM<br />

Q5. How long can a traveller take different anti<strong>malaria</strong>l drugs?<br />

A. <strong>Guidel<strong>in</strong>es</strong> <strong>for</strong> <strong>the</strong> long term use of <strong>malaria</strong> tablets are summarised <strong>in</strong> chapter 7<br />

and were orig<strong>in</strong>ally published <strong>in</strong> 2003 by <strong>the</strong> ACMP 55 .<br />

The ma<strong>in</strong> issues <strong>in</strong>fluenc<strong>in</strong>g <strong>the</strong> choice of <strong>malaria</strong> chemoprophylaxis on a long-term<br />

basis are <strong>the</strong> same as <strong>for</strong> short-term, i.e. adverse event profile, ease of compliance<br />

and efficacy. However, <strong>the</strong> specific issue relat<strong>in</strong>g to advice on chemoprophylaxis <strong>for</strong><br />

<strong>the</strong> long-term traveller relates to current licens<strong>in</strong>g restrictions. Long term use of<br />

<strong>malaria</strong> chemoprophylaxis outside licens<strong>in</strong>g restrictions is based on <strong>the</strong> cumulative<br />

evidence of lack of harm ra<strong>the</strong>r than positive evidence of safety. This situation is<br />

unlikely to change.<br />

Chloroqu<strong>in</strong>e<br />

Chloroqu<strong>in</strong>e has been taken safely <strong>for</strong> periods of many years at doses used <strong>for</strong> <strong>malaria</strong><br />

chemoprophylaxis. However, <strong>the</strong>re has been concern expressed about <strong>the</strong> possible<br />

development of ret<strong>in</strong>al toxicity with long term use of chloroqu<strong>in</strong>e (or<br />

hydroxychloroqu<strong>in</strong>e, often used to treat rheumatologic disorders). Ret<strong>in</strong>al toxicity has<br />

been described <strong>in</strong> those on daily chloroqu<strong>in</strong>e dosage <strong>for</strong> rheumatic disorders. As a<br />

result, two thresholds <strong>for</strong> <strong>the</strong> risk of ret<strong>in</strong>opathy have been suggested:<br />

• A total cumulative dose of 100g of chloroqu<strong>in</strong>e base<br />

• A daily dose of 250mg base (4mg / kg) 80 .<br />

The first threshold would require an adult to take chloroqu<strong>in</strong>e cont<strong>in</strong>uously, weekly,<br />

<strong>for</strong> a period of six years. The second threshold is far <strong>in</strong> excess of <strong>the</strong> prophylactic<br />

dosage. It has been concluded that <strong>the</strong> risk of ret<strong>in</strong>opathy <strong>from</strong> prophylactic dosage<br />

alone is negligible 29 . Fur<strong>the</strong>r reassurance can be ga<strong>in</strong>ed <strong>from</strong> <strong>the</strong> fact that<br />

ret<strong>in</strong>opathy has only rarely been reported <strong>in</strong> patients tak<strong>in</strong>g weekly prophylactic<br />

dosages 80,81 .<br />

ACMP advice suggests that chloroqu<strong>in</strong>e can be taken on a long-term basis. However,<br />

physicians should consider an ophthalmologic exam<strong>in</strong>ation every 6 -12 months ,<br />

beg<strong>in</strong>n<strong>in</strong>g at 6 years' cumulative use <strong>for</strong> those on long-term chloroqu<strong>in</strong>e.<br />

Proguanil<br />

There is no time limit specified <strong>for</strong> <strong>the</strong> use of proguanil. There<strong>for</strong>e, it can be taken<br />

cont<strong>in</strong>uously <strong>for</strong> several years.<br />

Mefloqu<strong>in</strong>e<br />

There are few data on <strong>the</strong> use of mefloqu<strong>in</strong>e <strong>for</strong> periods exceed<strong>in</strong>g two years,<br />

although <strong>the</strong>re is no evidence of cumulative toxicity, and mefloqu<strong>in</strong>e taken <strong>for</strong> over<br />

1 year is well tolerated. The product licence suggests mefloqu<strong>in</strong>e can be taken<br />

cont<strong>in</strong>uously <strong>for</strong> a period of up to 12 months. However, advice <strong>from</strong> <strong>the</strong> ACMP<br />

<strong>in</strong>dicates that <strong>the</strong>re is no evidence of harm <strong>in</strong> long term use if <strong>the</strong> drug is tolerated <strong>in</strong><br />

<strong>the</strong> short term, and suggests that mefloqu<strong>in</strong>e can be used safely <strong>for</strong> up to three years<br />

<strong>in</strong> <strong>the</strong> absence of side effects.<br />

87

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!